Cargando…
Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design
AIMS: Sleep‐disordered breathing (SDB) is a highly prevalent co‐morbidity in patients with chronic heart failure (CHF) and can play a detrimental role in the pathophysiology course of CHF. However, the best way to manage SDB in CHF remains a matter of debate. Sacubitril–valsartan has been included i...
Autores principales: | Jaffuel, Dany, Molinari, Nicolas, Berdague, Philippe, Pathak, Atul, Galinier, Michel, Dupuis, Marion, Ricci, Jean‐Etienne, Mallet, Jean‐Pierre, Bourdin, Arnaud, Roubille, François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933955/ https://www.ncbi.nlm.nih.gov/pubmed/29469206 http://dx.doi.org/10.1002/ehf2.12270 |
Ejemplares similares
-
Sacubitril‐valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO‐SAS study
por: Jaffuel, Dany, et al.
Publicado: (2021) -
Dapagliflozin initiation in chronic heart failure patients improves central sleep apnoea
por: Jaffuel, Dany, et al.
Publicado: (2023) -
Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)
por: Eadie, Ashley L., et al.
Publicado: (2021) -
Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril/Valsartan (Entresto™) in a 63-Year-Old Woman
por: Faber, Eve S., et al.
Publicado: (2016) -
Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?
por: Nikolic, Marina, et al.
Publicado: (2022)